<DOC>
	<DOCNO>NCT01701089</DOCNO>
	<brief_summary>This open-label , multiple dose , parallel group study assess monoamine oxidase brain vivo positron emission tomography ( PET ) safety RO4602522 patient Alzheimer disease healthy volunteer . Patients volunteer receive multiple dos RO4602522 three injection C11-L-deprenyl-D2 use PET .</brief_summary>
	<brief_title>A Study RO4602522 Patients With Alzheimer Disease Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Selegiline</mesh_term>
	<criteria>General : Adults 5080 year age . Females must nonchildbearing potential childbearing potential must use acceptable form contraception Body mass index ( BMI ) 18.032.0 kg/m2 inclusive Healthy volunteer : Healthy , clinically relevant find physical examination screen Day 1 No suspicion cognitive impairment/early dementia neuropsychological battery judge investigator Able participate willing give inform consent , comply study restriction . Alzheimer Disease ( AD ) patient : Probable Alzheimer 's disease , base National Institute Neurological Communicative Disorders Stroke ( NINCDS/ADRDA ) DSMIV criterion Have MMSE score screen 17 26 inclusive Modified Hachinski Ischemia Scale score &lt; /=4 A neuroimaging evaluation brain MRI support diagnosis AD , evidence focal disease account dementia MRI exclusion criterion Medications take symptomatic treatment AD must maintain stable dosage regimen least 1 month Day 1 . Able participate schedule evaluation The patient appropriate caregiver community dwell caregiver capable accompany subject visit center judge investigator . In opinion investigator patient caregiver compliant high probability complete study . Signed date write informed consent obtain patient , cosign patient 's close relative legally authorize representative , require national law patient incapable give informed consent . General : Any active disease gastrointestinal ( GI ) system , liver , kidney could result altered absorption , excess accumulation , impaired metabolism excretion drug , include history major upper middle GI tract surgery current significant chronic disease GI tract Clinically relevant abnormal history , physical finding , ECG , laboratory value screen assessment History cancer past five year , except fully treat local basal carcinoma , fully treat carcinoma situ cervix Any major illness occur within 1 month prior screen examination febrile illness within 5 day prior first dose History psychotropic medicine abuse At risk suicide opinion investigator Yes question number 4 5 Suicidal Ideation section CSSRS Administration ionize radiation radioisotope research , diagnostics test therapy within 12 month prior present study would exceed local yearly radiation dose exposure participation research study ( except dental xrays , minimal plain film chest ankle Xrays ) subject regularly work ionize radiation radioactive material . Participation clinical study investigational drug within 3 month screen Positive test hepatitis B , hepatitis C , HIV screen Loss donation 450 mL blood 4 month screen donation plasma within 14 day screen . History drug abuse evidence drug abuse urine test perform screen Current alcohol abuse , regular intake 2 unit alcohol daily Coffee ( tea ) consumption &gt; 5 cup per day xanthine contain drink &gt; /1.5 liter/day Healthy volunteer : Family history Alzheimer 's disease 1st 2nd degree relative 75 year . Evidence history clinically significant neurological psychiatric disorder . AD Patients : Any neurological psychiatric condition specify exception Previous immunization therapy AD</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>